Pharmaceutical

ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Jun 3, 2025 - 06:00
ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles
Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.
Read the original article

Tags:

Previous Article

ASCO25: J&J’s Carvykti shows strong efficacy across multiple myeloma risk groups

Next Article

CirCode Biomed gains clearance from FDA for RNA drug HM2002

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pfizer shelves haemophilia gene therapy Beqvez amid low demand

Pfizer shelves haemophilia gene therapy Beqvez amid low...

Feb 23, 2025

STAT+: Pharmalittle: FDA approves over-the-counter Narcan; J&J exits the race for the first RSV vaccine

STAT+: Pharmalittle: FDA approves over-the-counter Narc...

Mar 30, 2023

STAT+: Pharmalittle: We’re reading about CVS dropping Humira coverage, pharma layoffs, and more

STAT+: Pharmalittle: We’re reading about CVS dropping H...

Jan 4, 2024